Evaluation of the abbott LCx HIV-1 RNA quantitative, a new assay for quantitative determination of human immunodeficiency virus type 1 RNA

J Clin Microbiol. 2000 Oct;38(10):3882-6. doi: 10.1128/JCM.38.10.3882-3886.2000.

Abstract

A new quantitative reverse transcription (RT)-PCR assay for human immunodeficiency virus type 1 (HIV-1) RNA (Abbott LCx HIV RNA Quantitative assay) has been compared with the Organon NucliSens assay on 521 retrospective samples obtained from HIV-1-positive patients monitored during highly active antiretroviral therapy, 79 of whom were assayed also by the Chiron Quantiplex 3.0 system and on characterized panels. The LCx system showed a moderate correlation (r = 0.795) and gave higher results than the NucliSens system on 245 of 327 concordant positive samples, with similar sensitivity. Correlation with Quantiplex system results was higher (r = 0.943). LCx reproducibility was very good; the procedure was simple, well controlled, and rapid (up to 48 results in 7 h). The HIV RNA quantitative assay on the LCx system is suitable for routine use.

Publication types

  • Comparative Study

MeSH terms

  • Antiretroviral Therapy, Highly Active
  • HIV Infections / blood
  • HIV Infections / drug therapy*
  • HIV Seropositivity / blood
  • HIV Seropositivity / drug therapy*
  • HIV-1 / isolation & purification*
  • Humans
  • Polymerase Chain Reaction / methods
  • RNA, Viral / blood*
  • Reagent Kits, Diagnostic*
  • Regression Analysis
  • Reproducibility of Results
  • Retrospective Studies
  • Reverse Transcriptase Polymerase Chain Reaction*
  • Sensitivity and Specificity
  • Viral Load

Substances

  • RNA, Viral
  • Reagent Kits, Diagnostic